This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Top Message >> Message Archive (January 1, 2019)

PRINT

To Our Investors

Happy New Year!
The curtain has now opened on the final year of the Heisei period. I would like to sincerely thank the shareholders and everyone else who has continually supported Japan Tissue Engineering (J-TEC).
As we usher in the new year, I would like to offer a New Year’s greeting and say a little about my aspirations for this coming year while reflecting deeply on the various opinions expressed by the shareholders last year.

The challenges we face

Ken-ichiro Hata
President & CEO Ken-ichiro Hata

The fiscal year before last and last fiscal year as well, our company achieved profitability.
However, our pipeline is not yet rock solid, and I do not think that we have fully met the needs of the patients who are awaiting regenerative medicine, or of the people at the front lines of medicine and everyone else who is waiting for regenerative medicine to become a full-fledged industry. When our company was first established, we set the goals of first bringing regenerative medical products to the market and then promoting their widespread adoption. Autologous cultured epidermis JACE has met the urgent goal of emergency care for severe burns etc. by putting regenerative medical products on the market. Autologous cultured cartilage JACC was then launched to promote widespread adoption, but unfortunately it is still not indicated for the knee osteoarthritis that many elderly people suffer from.

“Making regenerative medicine common practice in treating patients” – This is the goal that our company has set for itself as we strive to deliver regenerative medicine to greater numbers of patients. It will mean targeting the diseases that trouble a larger number of patients. I am confident that you will come to understand this philosophy through the development pipeline that we have indicated, as well as through the various pipelines we will point out at every opportunity in the days to come.

Letting people know more about us

Thus far, our company has continued to explain regenerative medicine and the content of our business as carefully as possible. We have done what we can to collaborate in various events involving cooperation among industry, government, and academia, and we have laid the foundation for obtaining support from many directions as a leading company in this field. I think that these activities have been extremely important from the standpoint of smoothly proceeding with our company’s business.

This year, we will make renewed efforts to give more people an understanding of the importance of regenerative medicine and the development of the kind of regenerative medicine industry we have in mind. We will make proactive efforts to send out information by reacknowledging that the value of our company can be raised even further when people gain a deeper understanding of the activities of J-TEC. Now is the crucial moment, both for our own company and for the establishment of regenerative medicine as an industry. I hope that you all will lend us even greater support with a deeper understanding of this situation.

To all of our shareholders

At the end of last year, we sent out our company report in the form of a desktop calendar, as has been our custom. We thought long and hard over whether or not to make this expenditure because we needed money to introduce a new development pipeline, and sales of regenerative medicine products were lackluster. In order to send out the calendars, our young employees took the initiative in producing them, and with the cooperation of the vendor who handled the printing for us, it was possible to produce the calendars at a very low cost this year as well.

Our company is growing, and at least for this year, we should remain a healthy corporation that can meet the expectations of all. We have an energetic staff that will work hard to make this so. I hope that all of our shareholders will remember this by keeping the calendar nearby every day for the coming year.

Our goal for the near future is to set our management on a rock-solid foundation by making “regenerative medicine that can be delivered to large numbers of patients” a reality. It is my earnest wish to repay the kindness of our shareholders by building a sturdy regenerative medicine company and recycling the profits back to the shareholders. It would make me happy if you would continue to watch over us this year just a little longer as we complete this process. In 2019, as before, I promise to do everything in my power to promote the development of our business.

January 1, 2019
Kenichiro Hata
President & CEO
Japan Tissue Engineering Co., Ltd.